Monday, 14 June 2010

Teriflunomide in Adjunct to Interferon Beta Significantly Improved Outcomes of Multiple Sclerosis Patients

From MS News Today:
Caroline says: The age of orals is upon us...teriflumomide (Sanofi) added to beta interferon produced favorable outcomes when studied alone or as an adjunct to beta interferon. This is a Phase II study, which means this is a long way from FDA approval (interesting to keep on your radar, nonetheless).

http://www.msnewstoday.com/teriflunomide-in-adjunct-to-interferon-beta-significantly-improved-outcomes-of-multiple-sclerosis-patients/